Menu Search
Equities

Viemed Healthcare Inc

VIJ:DEU

Viemed Healthcare Inc

Actions
  • Price (EUR)9.10
  • Today's Change0.75 / 8.98%
  • Shares traded0.00
  • 1 Year change+35.82%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Viemed Healthcare Inc grew revenues 31.82% from 138.83m to 183.01m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 64.63% net income growth from 6.22m to 10.24m.
Gross margin60.28%
Net profit margin4.88%
Operating margin7.81%
Return on assets6.56%
Return on equity8.92%
Return on investment8.40%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Viemed Healthcare Inc fell by 4.08m. However, the company earned 45.21m from its operations for a Cash Flow Margin of 24.70%. In addition the company generated 2.83m cash from financing while 52.11m was spent on investing.
Cash flow per share0.8747
Price/Cash flow per share10.44
Book value per share3.21
Tangible book value per share2.34
More ▼

Balance sheet in USDView more

Viemed Healthcare Inc uses little debt in its capital structure as supported by a debt to capital ratio of 4.89%.
Current ratio1.31
Quick ratio1.19
Total debt/total equity0.0522
Total debt/total capital0.0489
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)1.15
EPS (TTM) vs
TTM 1 year ago		12.29
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.